Glatiramer Acetate
A random synthetic copolymer of four amino acids rather than a single defined peptide, approved by the FDA on December 20, 1996 as Copaxone for relapsing multiple sclerosis and available in 20 and 40 mg/mL injections and generic versions.
Also referenced as: Glatiramer, Copolymer 1, Copolymer-1, Cop 1, COP-1, Copaxone, Glatopa, Brabio
Public product evidence No certificate records are bound to a tracked Glatiramer Acetate product page A record counts here only when a vendor publishes a certificate against one of its own tracked Glatiramer Acetate product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Glatiramer, Copolymer 1, Copolymer-1, Cop 1, COP-1, Copaxone, Glatopa, Brabio
FDA label signal · 148 trials · 2316 PubMed results
Glatiramer Acetate is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Glatiramer Acetate has 23 name-matched clinical trials (highest phase: Phase 4) and 2316 PubMed-indexed publications and holds an FDA drug label. 13 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Glatiramer Acetate?
Glatiramer acetate is not a single defined peptide. The US label describes it as the acetate salts of synthetic polypeptides containing four naturally occurring amino acids, L-glutamic acid, L-alanine, L-tyrosine and L-lysine, at average molar fractions of 0.141, 0.427, 0.095 and 0.338, with an average molecular weight of 5,000 to 9,000 daltons. The amino acids are polymerized at random, so the product is a heterogeneous mixture of chains of varying length and sequence, defined by its composition and molecular-weight range rather than by a structure. It was first made at the Weizmann Institute of Science as copolymer 1 (Cop 1), a synthetic polymer designed to resemble myelin basic protein and induce experimental allergic encephalomyelitis in animals; it instead suppressed the disease (Teitelbaum et al., European Journal of Immunology, 1971;1(4):242–248).
Teva’s Copaxone was approved by the FDA on December 20, 1996 under NDA 020622 as a 20 mg daily subcutaneous injection for relapsing-remitting multiple sclerosis, and a 40 mg/mL strength given three times a week was added on January 28, 2014. The current indication covers relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, in adults. US generics date from Sandoz’s Glatopa on April 16, 2015; Copaxone was approved in Japan on September 28, 2015, and the European Union authorizes Copaxone and follow-on products such as Synthon’s Brabio through national and decentralized procedures. Glatiramer acetate has no footprint in the research-peptide market.
How it works
- Competes with myelin antigens for MHC class II. Biotinylated copolymer 1 binds directly and rapidly, without processing, to class II major histocompatibility complex molecules on living antigen-presenting cells of many mouse and human haplotypes, and it inhibits and even displaces the binding of myelin basic protein and its immunodominant p84-102 epitope (Fridkis-Hareli et al., Proceedings of the National Academy of Sciences, 1994;91(11):4872–4876).
- Shifts glatiramer-reactive T cells from Th1 toward Th2. Among 721 copolymer-1-reactive T-cell lines, lines from untreated patients and healthy donors mostly produced interferon-gamma, while lines from treated patients mostly produced IL-4, and longitudinal sampling showed the profile moving from Th1 to Th2 during treatment (Neuhaus et al., Proceedings of the National Academy of Sciences, 2000;97(13):7452–7457). Daily injections also abolished the proliferative T-cell response to the copolymer and promoted IL-5 and IL-13 secretion (Duda et al., Journal of Clinical Investigation, 2000;105(7):967–976).
- Bystander suppression inside the central nervous system. Copolymer-1-induced Th2 suppressor T-cell lines cross-react with myelin basic protein and ameliorated experimental autoimmune encephalomyelitis induced by two unrelated proteolipid protein epitopes (Aharoni et al., Journal of Neuroimmunology, 1998;91(1-2):135–146). The US label calls the mechanism not fully understood, with glatiramer acetate-specific suppressor T cells thought to be induced in the periphery.
- Reprograms monocytes. In mice, glatiramer acetate promoted anti-inflammatory type II monocytes (more IL-10 and TGF-beta, less IL-12 and TNF) that directed Th2 and regulatory T-cell differentiation independent of antigen specificity, and their adoptive transfer reversed established experimental autoimmune encephalomyelitis (Weber et al., Nature Medicine, 2007;13(8):935–943).
Research status
Pilot and pivotal trials. In a single-center, double-blind pilot, 50 patients self-injected Cop 1 or saline daily for two years; 56% of Cop 1 patients and 26% of placebo patients had no exacerbations (P = 0.045) (Bornstein et al., New England Journal of Medicine, 1987;317(7):408–414). The Copolymer 1 Multiple Sclerosis Study Group then randomized 251 patients at 11 US centers to 20 mg daily or placebo for two years: the two-year relapse rate was 1.19 versus 1.68, a 29% reduction (P = 0.007), more treated patients improved on the EDSS (P = 0.037), and a transient systemic reaction after injection occurred in 15.2% versus 3.2% (Johnson et al., Neurology, 1995;45(7):1268–1276). These are the first two clinical studies in the US label.
European/Canadian MRI study. In 239 patients with at least one enhancing lesion at screening, nine months of daily 20 mg glatiramer acetate reduced the total number of enhancing T1 lesions on monthly scans (difference −10.8, 95% CI −18.0 to −3.7; P = 0.003) and the relapse rate by 33% (P = 0.012) (Comi et al., Annals of Neurology, 2001;49(3):290–297).
PreCISe. In 481 patients with a clinically isolated syndrome and at least two T2 brain lesions treated for up to 36 months, glatiramer acetate reduced the risk of conversion to clinically definite multiple sclerosis by 45% (hazard ratio 0.55, 95% CI 0.40 to 0.77; P = 0.0005) and lengthened the time for 25% of patients to convert from 336 to 722 days (Comi et al., Lancet, 2009;374(9700):1503–1511). The clinically isolated syndrome population was added to the US label through an efficacy supplement approved February 27, 2009.
PROMiSe: failure in primary progressive disease. A three-year trial in 943 patients with primary progressive multiple sclerosis was stopped at an interim analysis; the delay in time to sustained disability was not significant (hazard ratio 0.87, 95% CI 0.71 to 1.07; P = 0.1753) (Wolinsky et al., Annals of Neurology, 2007;61(1):14–24). No progressive-disease indication followed.
Head-to-head and combination trials. REGARD randomized 764 patients to subcutaneous interferon beta-1a or glatiramer acetate 20 mg daily for 96 weeks and found no difference in time to first relapse (hazard ratio 0.94, 95% CI 0.74 to 1.21; P = 0.64) (Mikol et al., Lancet Neurology, 2008;7(10):903–914). BEYOND, in 2,244 patients, found no differences in relapse risk, EDSS progression or MRI measures between two doses of interferon beta-1b and 20 mg glatiramer acetate (O’Connor et al., Lancet Neurology, 2009;8(10):889–897). In CombiRx, 1,008 participants received weekly intramuscular interferon beta-1a, daily glatiramer acetate or both for at least three years: the combination was not superior to glatiramer acetate alone on relapse risk, which glatiramer acetate reduced more than interferon did (Lublin et al., Annals of Neurology, 2013;73(3):327–340). In CONFIRM, as a reference comparator for dimethyl fumarate, glatiramer acetate cut the annualized relapse rate to 0.29 versus 0.40 on placebo, a 29% reduction (P = 0.01), against 44% and 51% for the two dimethyl fumarate arms (Fox et al., New England Journal of Medicine, 2012;367(12):1087–1097).
GALA and the 40 mg strength (NCT01067521). The Glatiramer Acetate Low-Frequency Administration trial randomized 1,404 patients in 17 countries, 2:1, to 40 mg glatiramer acetate three times weekly or placebo for 12 months. The regimen reduced the risk of confirmed relapse by 34.0% (annualized relapse rate 0.331 versus 0.505; P < 0.0001), cut gadolinium-enhancing T1 lesions by 44.8% and new or enlarging T2 lesions by 34.7%, and caused injection-site reactions in 35.5% versus 5.0% (Khan et al., Annals of Neurology, 2013;73(6):705–713). In the open-label extension, 1,041 patients reached three years with annualized relapse rates of 0.20 to 0.22 (Khan et al., Multiple Sclerosis, 2017;23(6):818–829). Drugs@FDA lists the regimen as efficacy supplement S-089.
GATE and generic equivalence (NCT01489254). Synthon’s Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone randomized 794 patients 4.3:4.3:1 to generic glatiramer acetate 20 mg, brand 20 mg or placebo daily for nine months. Both active arms beat placebo on gadolinium-enhancing lesions (ratio 0.488), and the generic-to-brand ratio of 1.095 (95% CI 0.883 to 1.360) fell within the prespecified equivalence margin of 0.727 to 1.375, with similar adverse events (Cohen et al., JAMA Neurology, 2015;72(12):1433–1441). In the 15-month open-label extension, patients switched from brand to generic showed no difference in relapse rate, MRI activity or anti-drug antibody titers from those continuing the generic (Selmaj et al., Multiple Sclerosis, 2017;23(14):1909–1917). In the US, Drugs@FDA lists Glatopa 20 mg/mL (Sandoz, ANDA 090218) approved April 16, 2015, Mylan’s two strengths on October 3, 2017, Glatopa 40 mg/mL on February 12, 2018, Synthon’s on September 25, 2024, Chemi’s on May 7, 2025, ScinoPharm’s on December 31, 2025 and Hybio’s on February 11, 2026.
Safety. The label reports an immediate post-injection reaction in about 16% of patients on 20 mg daily versus 4% on placebo. An FDA pharmacovigilance review identified 82 cases of anaphylaxis, six fatal, occurring from 1 week to 72 months after starting treatment, including 19 cases more than a year in; the labeling supplement adding a boxed warning for anaphylaxis was approved January 22, 2025 (Kim et al., Multiple Sclerosis, 2025;31(14):1664–1671). Teva’s database of more than 7,000 exposed pregnancies found no higher risk of congenital anomalies than general-population registries (Sandberg-Wollheim et al., International Journal of MS Care, 2018;20(1):9–14).
Common dosage forms
- Copaxone 20 mg/mL. A single-dose prefilled syringe with a white plunger, containing 20 mg of glatiramer acetate in 1 mL, for subcutaneous self-injection.
- Copaxone 40 mg/mL. A single-dose prefilled syringe with a blue plunger, containing 40 mg in 1 mL; the label states that the two strengths are not interchangeable.
- Generic glatiramer acetate injection. Glatopa (Sandoz) and glatiramer acetate injection from Mylan, Synthon, Chemi, ScinoPharm and Hybio in 20 mg/mL and 40 mg/mL prefilled syringes.
- Discontinued presentation. Copaxone 20 mg per vial lyophilized powder for solution, the original 1996 presentation, is listed in Drugs@FDA as discontinued.
- Outside the US. Copaxone 20 mg prefilled syringes in Japan; Copaxone, Brabio and other glatiramer acetate products in the European Union.
Key considerations
- Regulatory status. The FDA Approved status reflects the December 20, 1996 approval of Copaxone (glatiramer acetate injection) under NDA 020622 for relapsing-remitting multiple sclerosis. The 40 mg/mL strength was approved on January 28, 2014, the first US generic followed on April 16, 2015, and the label gained a boxed warning for anaphylaxis in January 2025.
- A mixture, not a peptide. Glatiramer acetate is a random copolymer defined by amino-acid ratios and a molecular-weight range rather than by a sequence. The Synthon generic was tested in a dedicated equivalence trial, and the label states that the 20 mg and 40 mg products are not interchangeable with each other.
- Moderate efficacy, well characterized. Relapse-rate reductions against placebo have been consistent at roughly 29 to 34%, matching the interferons in head-to-head trials and falling short of dimethyl fumarate; the drug failed in primary progressive disease and carries no indication there.
- Anaphylaxis can be late and can mimic the post-injection reaction. The 2025 boxed warning rests on cases that began up to years after the first dose, with symptoms that overlap the common, self-limited immediate post-injection reaction, so a reaction long into treatment is not automatically benign.
- Naming. Copolymer 1, Cop 1, glatiramer, glatiramer acetate, Copaxone, Glatopa and Brabio all denote the same random copolymer product, marketed as the acetate salt, and none has a research-peptide-market counterpart.